Polymyalgia rheumatica (PMR) is an inflammatory rheumatic condition that causes severe stiffness and aching in the shoulders, neck, and hip girdle — turning everyday movements like raising an arm or rising from a chair into genuine hardship. It affects adults almost exclusively over age 50 and is closely linked to giant cell arteritis, a potentially sight-threatening vasculitis. The cornerstone of treatment is corticosteroids, which often work dramatically within days. But for the substantial minority of patients who cannot taper below a threshold dose without relapse, or who suffer intolerable steroid side effects, the medical toolbox has been frustratingly limited. Mesenchymal stem cell therapy is now being studied as a way to address the underlying immune dysregulation rather than simply suppress it.[1][2]

What goes wrong in polymyalgia rheumatica

Polymyalgia rheumatica is an autoinflammatory condition centered on the proximal joints — shoulders and hips — driven by a dysregulated innate immune response. Unlike rheumatoid arthritis, PMR does not primarily involve joint erosion or autoantibodies. Instead, the pathology revolves around IL-6, a master cytokine that orchestrates the systemic inflammation, morning stiffness, and acute-phase response characteristic of the disease.[3]

The IL-6 cascade. Activated dendritic cells and macrophages in the synovium and bursae release IL-6, which stimulates the liver to produce C-reactive protein (CRP) and drives the constitutional symptoms — fatigue, low-grade fever, weight loss — that often accompany PMR. IL-6 also promotes differentiation of Th17 cells and suppresses regulatory T-cell function, tilting the immune balance toward sustained inflammation.[4]

The corticosteroid trap. Prednisolone at 15–20 mg/day typically produces a dramatic response within 48–72 hours — so reliable that a rapid response is itself a diagnostic criterion. The problem is what comes next. Many patients require treatment for 1–3 years, and a significant proportion — estimates range from 30% to 60% — cannot taper below 5–7.5 mg/day without experiencing recurrent symptoms. Prolonged corticosteroid exposure brings its own burden: osteoporosis, diabetes, hypertension, cataracts, and increased infection risk. This is the clinical gap that MSC research aims to fill.[5]

Why mesenchymal stem cells are a candidate for PMR

The therapeutic rationale for MSCs in polymyalgia rheumatica rests on a remarkably close fit between MSC biology and PMR pathology. MSCs are the body's most potent endogenous immunomodulators — they sense inflammatory signals and respond with a coordinated anti-inflammatory program that targets the very pathways driving PMR.[6][7]

Direct IL-6 suppression. MSCs secrete soluble factors including TSG-6, PGE2, and IDO that directly downregulate IL-6 production by activated macrophages and dendritic cells. In pre-clinical models, MSC infusion reduces systemic IL-6 levels within hours — a mechanism that maps directly onto the IL-6-driven pathology of PMR.

Treg expansion and Th17 restraint. MSCs promote the expansion of regulatory T-cells (Tregs) while suppressing Th17 differentiation, rebalancing the immune system toward tolerance. This is the same mechanism that has shown early promise in other inflammatory rheumatic conditions such as rheumatoid arthritis and lupus, where Treg–Th17 imbalance is central to disease persistence.[8]

Macrophage polarization. MSCs shift macrophages from the pro-inflammatory M1 phenotype to the anti-inflammatory, tissue-repair M2 phenotype — reducing the local production of TNF-α and IL-1β while promoting resolution of inflammation. In the context of PMR, where bursal and synovial macrophage activation is a core feature, this mechanism is particularly relevant.[9]

What the research shows — and what it doesn't

The evidence for MSC therapy in PMR is at an earlier stage than for some other rheumatic conditions. No dedicated PMR-specific MSC trial has yet been completed. However, the research landscape is populated by studies in closely related inflammatory conditions that share the same IL-6-driven pathophysiology — giant cell arteritis, rheumatoid arthritis, and other autoinflammatory syndromes — and by a growing body of mechanistic data that supports the biological rationale.

Relevant clinical signals. In small trials of MSC therapy for rheumatoid arthritis and systemic lupus erythematosus, infusion of umbilical-cord-derived MSCs produced measurable reductions in inflammatory markers including CRP and ESR, alongside improvements in disease-activity scores. Some studies have reported sustained reductions in IL-6 levels for weeks to months post-infusion. While these are not PMR trials, the shared IL-6-driven inflammatory axis makes the findings relevant to the PMR question.[10]

The corticosteroid-sparing potential. Perhaps the most clinically relevant question for PMR patients is whether MSC therapy could reduce the required corticosteroid dose — or enable tapering in patients who are steroid-dependent. In animal models of inflammatory disease, MSC infusion has been shown to maintain disease control while allowing corticosteroid dose reduction. This has not yet been specifically tested in a PMR cohort, but it represents the most compelling translational rationale for the field.

The honest headline

As of today, MSC therapy has not been proven to treat polymyalgia rheumatica in a dedicated clinical trial. The biological rationale — IL-6 suppression, Treg expansion, and macrophage reprogramming — is strong and maps directly onto PMR pathology. The relevant research in adjacent inflammatory conditions has produced encouraging safety data and preliminary signals of immunomodulatory benefit. But no PMR-specific efficacy data exist, and anyone presenting MSC therapy as a proven treatment for PMR is going beyond what the evidence supports.

How PMR outcomes are measured — and what MSC therapy would need to show

For MSC therapy to be taken seriously in PMR, it would need to demonstrate benefit using the same rigorous measures that rheumatologists apply to existing treatments. The PMR-AS (Polymyalgia Rheumatica Activity Score) combines morning stiffness duration, the ability to elevate the upper limbs, physician global assessment, and CRP into a validated composite score. Cumulative corticosteroid dose over 12–24 months is arguably the most meaningful outcome — a therapy that reduces total steroid exposure by even 30% would represent clinically significant progress. Relapse-free survival during steroid tapering is another critical endpoint, since the defining problem in PMR is the inability to discontinue corticosteroids without disease recurrence.

How to evaluate any offer responsibly

If you are considering stem cell options for PMR, the same principles of due diligence apply as for any investigational therapy. Ask whether the treatment is part of a registered clinical trial with ethical oversight and published protocols. Ask what cell source and dose are being used, and on what published evidence — not anecdotes or testimonials — the claims rest. Be deeply sceptical of guaranteed results, success-rate statistics without a citation, or any suggestion to discontinue prescribed corticosteroids without medical supervision. Abrupt corticosteroid withdrawal can trigger an adrenal crisis — a potentially life-threatening event that no legitimate provider would risk.

A responsible clinic will describe MSC therapy for PMR as an emerging area of research with a plausible biological rationale but no completed efficacy trials — and will never let hope outpace the data.

Polymyalgia rheumatica is exactly the kind of condition where false hope causes real harm — because the standard treatment works, but its long-term burden is heavy. The most respectful thing we can offer patients is the truth about where the science stands, and the patience to let rigorous investigation answer the questions that testimonials cannot.

— VELAR Clinical Team

The VELAR perspective

At VELAR Center, our clinical work is grounded in conditions where the regenerative evidence base is more mature. We follow the MSC research in autoinflammatory disease closely because the IL-6-centered biology of PMR makes it a compelling target for immunomodulatory cell therapy — but we believe the only honest way to discuss it is with plain language: the rationale is sound, the relevant research in adjacent conditions is encouraging, the corticosteroid-sparing potential is the most exciting translational question, and it remains investigational. As the evidence matures, we will let that evidence — not enthusiasm — shape anything we say about it. If you are living with PMR and want an honest, evidence-based conversation about what regenerative medicine can and cannot do today, that is exactly where a responsible consultation begins.

Frequently Asked Questions

Can stem cell therapy cure polymyalgia rheumatica?

No stem cell therapy has been proven to cure PMR. MSC therapy is being researched for its potential to modulate the IL-6-driven inflammation that causes PMR, with the goal of reducing disease activity and corticosteroid dependence — not as a cure. The research is at an early, investigational stage with no completed PMR-specific efficacy trials.

How much does stem cell therapy for PMR cost in Thailand?

MSC therapy costs in Thailand vary widely depending on cell source, dose, and clinic. As PMR-specific treatment remains investigational with no standardized protocol, pricing is not standardized. For a transparent discussion of costs and what regenerative options may be appropriate, a consultation with the VELAR clinical team is the recommended starting point.

Could MSC therapy help me reduce my prednisolone dose?

Corticosteroid sparing is theoretically the most compelling potential application of MSC therapy in PMR. In animal models and small human studies in related inflammatory conditions, MSCs have demonstrated the ability to maintain disease control while allowing corticosteroid dose reduction. However, this has not been specifically tested in a PMR patient population, and no clinical recommendation can yet be made.

Is MSC therapy safe for older adults with PMR?

The safety data from MSC trials across multiple conditions — including studies in older adults — have been generally reassuring. No serious short-term safety signals attributable to the cells themselves have been consistently reported. However, the safety of MSC therapy has not been specifically studied in a PMR cohort, and each patient's individual risk profile — including cardiovascular status and concurrent medications — must be assessed by a qualified clinician.

What is the difference between PMR and rheumatoid arthritis?

While both are inflammatory rheumatic conditions, PMR primarily affects the proximal muscles and joints (shoulders, hips, neck) with severe stiffness rather than joint destruction. RA involves synovial inflammation leading to cartilage and bone erosion, is associated with autoantibodies (RF, anti-CCP), and typically affects smaller joints (hands, wrists, feet) symmetrically. Both involve IL-6-driven inflammation, which is why MSC immunomodulation is relevant to both conditions — but they are distinct diseases with different treatment paradigms.

References

  1. Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. The Lancet. 2008;372(9634):234-245. doi:10.1016/S0140-6736(08)61077-6 ↩
  2. Dasgupta B, Cimmino MA, Maradit-Kremers H, et al. 2012 provisional classification criteria for polymyalgia rheumatica. Annals of the Rheumatic Diseases. 2012;71(4):484-492. doi:10.1136/annrheumdis-2011-200329 ↩
  3. Roche NE, Fulbright JW, Wagner AD, Hunder GG, Goronzy JJ, Weyand CM. Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica. Arthritis & Rheumatism. 1993;36(9):1286-1294. doi:10.1002/art.1780360913 ↩
  4. Weyand CM, Goronzy JJ. Immune mechanisms in medium and large-vessel vasculitis. Nature Reviews Rheumatology. 2013;9(12):731-740. doi:10.1038/nrrheum.2013.161 ↩
  5. Mackie SL, Mallen CD. Polymyalgia rheumatica. BMJ. 2013;347:f6937. doi:10.1136/bmj.f6937 ↩
  6. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nature Reviews Immunology. 2008;8(9):726-736. doi:10.1038/nri2395 ↩
  7. Shi Y, Wang Y, Li Q, et al. Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases. Nature Reviews Nephrology. 2018;14(8):493-507. doi:10.1038/s41581-018-0023-5 ↩
  8. Wang Y, Chen X, Cao W, Shi Y. Plasticity of mesenchymal stem cells in immunomodulation. Nature Immunology. 2014;15(11):1009-1016. doi:10.1038/ni.3002 ↩
  9. Németh K, Leelahavanichkul A, Yuen PST, et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E2-dependent reprogramming of host macrophages. Nature Medicine. 2009;15(1):42-49. doi:10.1038/nm.1905 ↩
  10. Galipeau J, Sensébé L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell Stem Cell. 2018;22(6):824-833. doi:10.1016/j.stem.2018.05.004 ↩
  11. Pittenger MF, Discher DE, Péault BM, Phinney DG, Hare JM, Caplan AI. Mesenchymal stem cell perspective: cell biology to clinical progress. NPJ Regenerative Medicine. 2019;4:22. doi:10.1038/s41536-019-0083-6 ↩
  12. Lalu MM, McIntyre L, Pugliese C, et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell). PLoS One. 2012;7(10):e47559. doi:10.1371/journal.pone.0047559 ↩